PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICI) are extremely expensive and most patients with metastatic urothelial carcinoma (mUC) do not benefit significantly from their use. OBJECTIVE: We performed a systematic review and meta-analysis to determine response rates and survival outcomes on patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Wei Phin, Tan, Wei Shen, Inman, Brant A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919639/
https://www.ncbi.nlm.nih.gov/pubmed/31867425
http://dx.doi.org/10.3233/BLC-190238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919639/
https://www.ncbi.nlm.nih.gov/pubmed/31867425
http://dx.doi.org/10.3233/BLC-190238

Ejemplares similares